Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary Thyroid Carcinoma

This study highlights important distinctions between the genomes and transcriptomes of pediatric and adult papillary thyroid carcinoma, with implications for understanding the biology, diagnosis, and treatment of advanced disease in children. Pediatric papillary thyroid carcinoma (PPTC) is clinically distinct from adult-onset disease. Although there are higher rates of metastasis and recurrence in PPTC, prognosis remains highly favorable. Molecular characterization of PPTC has been lacking. Historically, only 40% to 50% of childhood papillary thyroid carcinoma (PTC) were known to be driven by genomic variants common to adult PTC; oncogenic drivers in the remainder were unknown. This contrasts with approximately 90% of adult PTC driven by a discrete number of variants. In this study, 52 PPTCs underwent candidate gene testing, followed in a subset by whole-exome and transcriptome sequencing. Within these samples, candidate gene testing identified variants in 31 (60%) tumors, while exome and transcriptome sequencing identified oncogenic variants in 19 of 21 (90%) remaining tumors. The latter were enriched for oncogenic fusions, with 11 nonrecurrent fusion transcripts, including two previously undescribed fusions, STRN-RET and TG-PBF. Most fusions were associated with 3′ receptor tyrosine kinase (RTK) moieties: RET, MET, ALK, and NTRK3. For advanced (distally metastatic) tumors, a driver variant was described in 91%. Gene expression analysis defined three clusters that demonstrated distinct expression of genes involved in thyroid differentiation and MAPK signaling. Among RET-CCDC6–driven tumors, gene expression in pediatric tumors was distinguishable from that in adults. Collectively, these results show that the genomic landscape of pediatric PTC is different from adult PTC. Moreover, they identify genomic drivers in 98% of PPTCs, predominantly oncogenic fusion transcripts involving RTKs, with a pronounced impact on gene expression. Notably, most advanced tumors were driven by a variant for which targeted systemic therapy exists. Significance: This study highlights important distinctions between the genomes and transcriptomes of pediatric and adult papillary thyroid carcinoma, with implications for understanding the biology, diagnosis, and treatment of advanced disease in children.

[1]  X. Qiu,et al.  Immunoglobulin Expression in Cancer Cells and Its Critical Roles in Tumorigenesis , 2021, Frontiers in Immunology.

[2]  S. Sherman,et al.  Distant metastases from childhood differentiated thyroid carcinoma: clinical course and mutational landscape. , 2020, The Journal of clinical endocrinology and metabolism.

[3]  A. Alzahrani,et al.  Genetic Alterations in Pediatric Thyroid Cancer Using a Comprehensive Childhood Cancer Gene Panel. , 2020, The Journal of clinical endocrinology and metabolism.

[4]  J. Wasserman,et al.  Lung metastasis in children with differentiated thyroid cancer: factors associated with diagnosis and outcomes of therapy. , 2020, Thyroid : official journal of the American Thyroid Association.

[5]  P. Vlcek,et al.  RET, NTRK, ALK, BRAF and MET fusions in a large cohort of pediatric papillary thyroid carcinomas. , 2020, Thyroid : official journal of the American Thyroid Association.

[6]  E. Christison-Lagay,et al.  Recurrence and Complications in Pediatric and Adolescent Papillary Thyroid Cancer in a High-Volume Practice. , 2020, The Journal of surgical research.

[7]  V. Vasko,et al.  PKA Activates AMPK Through LKB1 Signaling in Follicular Thyroid Cancer , 2019, Front. Endocrinol..

[8]  Simion I. Chiosea,et al.  Characterization of Thyroid Cancer Driven by Known and Novel ALK Fusions. , 2019, Endocrine-related cancer.

[9]  R. Gong,et al.  Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis , 2019, Endocrine.

[10]  B. Haas,et al.  Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods , 2019, Genome Biology.

[11]  M. Rugge,et al.  Differentiated Thyroid Carcinoma in Pediatric Age: Genetic and Clinical Scenario , 2019, Front. Endocrinol..

[12]  J. Biegel,et al.  Novel TRIM24-MET Fusion in a Neonatal Brain Tumor. , 2019, JCO precision oncology.

[13]  M. Luster,et al.  Management Guidelines for Children With Thyroid Nodules and Differentiated Thyroid Cancer , 2018, Pediatrics.

[14]  A. Alzahrani,et al.  Lung Metastasis in Pediatric Thyroid Cancer: Radiological Pattern, Molecular Genetics, Response to Therapy, and Outcome , 2018, The Journal of clinical endocrinology and metabolism.

[15]  Nicola D. Roberts,et al.  Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors , 2018, Science.

[16]  Y. Nikiforov,et al.  Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion. , 2018, The American journal of pathology.

[17]  Douglas B. Evans,et al.  Thyroid cancer in adolescents and young adults , 2018, Pediatric blood & cancer.

[18]  J. Wasserman,et al.  Young age is associated with increased rates of residual and recurrent paediatric differentiated thyroid carcinoma , 2018, Clinical Endocrinology.

[19]  Quan-Yong Luo,et al.  Pulmonary metastases in children and adolescents with papillary thyroid cancer in China: prognostic factors and outcomes from treatment with 131I , 2018, Endocrine.

[20]  A. Drilon,et al.  RET fusions in a small subset of advanced colorectal cancers at risk of being neglected , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  W. Foulkes,et al.  DICER1 Mutations Are Frequent in Adolescent-Onset Papillary Thyroid Carcinoma , 2018, The Journal of clinical endocrinology and metabolism.

[22]  Krishanpal Anamika,et al.  FusionHub: A unified web platform for annotation and visualization of gene fusion events in human cancer , 2018, PloS one.

[23]  A. Dobrovic,et al.  Optimizing Amplification of the GC-Rich TERT Promoter Region Using 7-Deaza-dGTP for Droplet Digital PCR Quantification of TERT Promoter Mutations. , 2018, Clinical chemistry.

[24]  M. Reinalda,et al.  Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936–2015) , 2018, World Journal of Surgery.

[25]  C. Antonescu,et al.  TFG‐MET fusion in an infantile spindle cell sarcoma with neural features , 2017, Genes, chromosomes & cancer.

[26]  R. Lloyd,et al.  WHO classification of tumours of endocrine organs , 2017 .

[27]  A. Bauer Molecular Genetics of Thyroid Cancer in Children and Adolescents. , 2017, Endocrinology and metabolism clinics of North America.

[28]  A. Hackshaw,et al.  Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer , 2017, Oncogene.

[29]  M. Hirokawa,et al.  Frequent BRAFV600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan , 2017, Endocrine Pathology.

[30]  C. Longui,et al.  Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children. , 2017, Thyroid : official journal of the American Thyroid Association.

[31]  E. Harley,et al.  Pediatric thyroid cancer: An update from the SEER database 2007-2012. , 2016, International journal of pediatric otorhinolaryngology.

[32]  Sun Wook Cho,et al.  Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers , 2016, PLoS genetics.

[33]  M. Nikiforova,et al.  NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States , 2016, Cancer.

[34]  S. Poyrazoglu,et al.  Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAFV600E Harboring Pediatric Papillary Thyroid Carcinomas , 2016, Endocrine Pathology.

[35]  S. Monaco,et al.  Molecular Characterization of Sporadic Pediatric Thyroid Carcinoma with the DNA/RNA ThyroSeq v2 Next-Generation Sequencing Assay , 2016, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[36]  F. Waldman,et al.  Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation , 2016, Thyroid : official journal of the American Thyroid Association.

[37]  L. McDaniel,et al.  Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population. , 2016, Archives of pathology & laboratory medicine.

[38]  O. Kallioniemi,et al.  FusionCatcher – a tool for finding somatic fusion genes in paired-end RNA-sequencing data , 2014, bioRxiv.

[39]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.

[40]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[41]  M. Pelizzola,et al.  DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes , 2014, Genome Medicine.

[42]  Lianbo Yu,et al.  Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice. , 2014, The Journal of clinical endocrinology and metabolism.

[43]  Christopher E Mason,et al.  Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. , 2013, The Journal of clinical investigation.

[44]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[45]  T. Soni Madhulatha,et al.  An Overview on Clustering Methods , 2012, ArXiv.

[46]  Silva Frieda,et al.  Thyroid Cancer in the Pediatric Population , 2012 .

[47]  G. Sassolas,et al.  Oncogenic alterations in papillary thyroid cancers of young patients. , 2012, Thyroid : official journal of the American Thyroid Association.

[48]  Christopher A. Maher,et al.  ChimeraScan: a tool for identifying chimeric transcription in sequencing data , 2011, Bioinform..

[49]  J. Franklyn,et al.  Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment. , 2011, Cancer research.

[50]  Süleyman Cenk Sahinalp,et al.  deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data , 2011, PLoS Comput. Biol..

[51]  Derek Y. Chiang,et al.  MapSplice: Accurate mapping of RNA-seq reads for splice junction discovery , 2010, Nucleic acids research.

[52]  L. Koniaris,et al.  Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. , 2009, The Journal of surgical research.

[53]  M. Phillip,et al.  Differentiated thyroid carcinoma in pediatric patients: comparison of presentation and course between pre-pubertal children and adolescents. , 2009, The Journal of pediatrics.

[54]  Keying Ye,et al.  Determining the Number of Clusters Using the Weighted Gap Statistic , 2007, Biometrics.

[55]  C. Reiners,et al.  Comprehensive Clinical Assessment of 740 Cases of Surgically Treated Thyroid Cancer in Children of Belarus , 2006, Annals of surgery.

[56]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Borrello,et al.  RET tyrosine kinase signaling in development and cancer. , 2005, Cytokine & growth factor reviews.

[58]  J. Franklyn,et al.  Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. , 2005, The Journal of clinical endocrinology and metabolism.

[59]  Masahiro Ito,et al.  Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.

[60]  Y. Shimizu-Yoshida,et al.  Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid carcinoma from externally irradiated patient. , 2003, Mutation research.

[61]  D. Harrison,et al.  G‐protein mutations in human pituitary adrenocorticotrophic hormone‐secreting adenomas , 1995, European journal of clinical investigation.

[62]  J. Cerutti,et al.  ETV6-NTRK3 and STRN-ALK kinase fusions are recurrent events in papillary thyroid cancer of adult population. , 2018, European journal of endocrinology.

[63]  L. Sullivan,et al.  Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions. , 2018, Thyroid : official journal of the American Thyroid Association.

[64]  Keiji Suzuki,et al.  Identification of Three Novel Fusion Oncogenes, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, in Thyroid Cancers of Young Patients in Fukushima. , 2017, Thyroid : official journal of the American Thyroid Association.